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NOVEL INSIGHTS INTO PROTEIN SYNTHESIS RATES IN THE BRAIN FOLLOWING 
TWO LIFESPAN-EXTENDING TREATMENTS 
 
 
The number of individuals 65 years or older is rapidly increasing. Aging is the 
predominant risk factor for chronic disease and disability. Dramatic increases in the 
number of individuals living with chronic disease or disability will present unique societal 
challenges. Accordingly, much research has focused on treatments that slow the aging 
process to prevent many chronic diseases simultaneously. Treatments using two 
pharmaceuticals, rapamycin and rapamycin plus metformin, have been shown to extend 
lifespan and improve health in model organisms. Neurodegenerative diseases represent 
an important subset of debilitating chronic diseases, for which treatment is currently 
limited. The use of slowed aging treatments in research of neurological function may 
provide insight into causes of neurodegenerative disease. Protein homeostasis 
(proteostasis) is crucial for cell and organismal health. Loss of proteostasis is 
characteristic of aging and chronic disease, and slowed aging treatments improve 
proteostasis-related outcomes. Protein synthesis is a necessary component of 
proteostasis. The effect of rapamycin and rapamycin plus metformin on protein 
synthesis rates in vivo is unexplored. Investigation into the effect of both slowed aging 
treatments on protein synthesis rates in the brain could inform effects on neuronal 
health, which may have implications for neurodegeneration. The purpose of the current 
study is to establish the use of deuterium oxide as a stable isotopic tracer for brain 
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protein synthesis rates in vivo, and to determine the effect of two slowed aging 
treatments on brain protein synthesis rates. Supportive measurements related to 
proteostasis were also made. Deuterium oxide labeling allowed for measurement of 
subcellular brain protein synthesis rates with ample sensitivity to detect sex differences 
and responses to treatment. The results demonstrated a strong influence of sex in 
response to both rapamycin and rapamycin plus metformin. Both slowed aging 
treatments had differing effects on protein synthesis as well as other markers of 
proteostasis. This study is the first to demonstrate the use of deuterium oxide for protein 
synthesis rates in the brain, which represents a novel methodology for evaluating 
proteostasis in neuronal tissue. Further, this is the first study to explore and reveal the 
effects of rapamycin and rapamycin with metformin on protein synthesis rates in the 
brain. Future studies using these methods and slowed aging interventions in models of 
neurodegenerative disease may prove insightful in determining causes, pathologies, 
and treatments of age-related neurological disorders. 
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CHAPTER I: INTRODUCTION 
 
The median age of the human population is rapidly increasing worldwide. In the 
United States alone, conservative estimates predict that by 2030 the number of 
individuals older than 65 years will exceed 70 million (Olshansky, Goldman, Zheng, & 
Rowe, 2009). This shift in part reflects increased life expectancy due to advancements 
in healthcare and higher standards of living (Harper, 2014). However, this sudden 
change will present unique societal issues given that aging is the predominant risk 
factor for many chronic diseases (Anton et al., 2015; Rowe & Kahn, 1998), including an 
important subset of debilitating chronic diseases that affect the central nervous system, 
known as neurological disorders (World Health Organization, 2006).  
The fact that aging is the leading risk factor for most chronic diseases suggests 
that aging is a target for preventing many chronic diseases simultaneously (Seals, 
Justice, & LaRocca, 2016). Despite the intricacies of aging, slowing the aging process 
may be an effective alternative to treating the primary etiology or individual symptoms of 
individual chronic diseases. For that reason, it is important to identify and understand 
the mechanistic causes of aging so that they may be targeted by slowed-aging 
treatments (Kennedy et al., 2014).  
Slowed aging treatments are currently the focus of much research (López-Otín, 
Galluzzi, Freije, Madeo, & Kroemer, 2016). Two pharmaceutical compounds, rapamycin 
and metformin, extend lifespan and improve health outcomes (Anisimov, 2013; Harrison 
et al., 2009). Both appear to exert their benefits through coordination of overlapping 
cellular signaling cascades. Metformin and rapamycin are tools for increasing scientific 
knowledge of the aging process. Alterations in the mammalian target of rapamycin 
 2 
(mTOR) signaling pathway are thought to underlie some of the beneficial effects of 
rapamycin and metformin treatment.  
The maintenance of protein function and concentration is of particular importance 
at both the cellular and organismal level. Protein homeostasis (proteostasis) is the result 
of the collective processes of protein folding, degradation, and synthesis (Balch, 
Morimoto, Dillin, & Kelly, 2008). Loss of proteostasis is associated with aging and many 
chronic diseases (Labbadia & Morimoto, 2015a; López-Otín, Blasco, Partridge, Serrano, 
& Kroemer, 2013). Loss of proteostasis appears to be particularly important in the 
context of neurodegenerative disease (Eftekharzadeh, Hyman, & Wegmann, 2016; 
Smith & Mallucci, 2016).  
Important regulators of proteostasis are under the control of mTOR (Laplante & 
Sabatini, 2009), and thus may be affected by rapamycin and metformin. In this way, 
treatment with rapamycin and metformin may be used to better understand the effects 
of slowed aging treatments on proteostatic maintenance in the brain. The information 
gained from experiments on slowed aging treatments in brain could inform mechanisms 
that underlie age-related neurodegeneration and the onset of neurodegenerative 
disorders, as well as how each can be prevented.  
Study purpose 
The purpose of this study was to evaluate the effect of the slowed aging 
treatments, rapamycin and metformin, on proteostatic maintenance in the brains of male 




Statement of Problem 
Proteostatic Maintenance is a complex and dynamic cellular process that is 
necessary for proper cell function and organismal health. The capacity for proteostatic 
maintenance decreases with age and in disease. The central nervous system is 
particularly sensitive to loss of proteostasis, which is a characteristic of many 
neurodegenerative diseases. The effect of the health-promoting and lifespan extending 
treatments on proteostatic maintenance in the brain has yet to be evaluated.   
Hypotheses 
We hypothesize that the slowed aging treatments, rapamycin and rapamycin plus 
metformin in combination, will improve the outcomes of various markers of proteostatic 
maintenance in the brains of young and old mice when compared to mice that receive 
























CHAPTER II: LITERATURE REVIEW 
 
An Aging Global Population 
The median age of the human population is rapidly increasing. In the United 
States, the number of individuals aged 65 years or older is expected to double between 
2000 and 2030 (Olshansky et al., 2009). By the year 2050, the aging demographic will 
constitute 25-40% of the total population of most developed nations (Petsko, 2008). 
Global life expectancy is roughly seventy years, the highest it has ever been (H. Wang 
et al., 2016). Increased life expectancy shifts the age composition of a population by 
increasing the proportion of older individuals in a given population. Simultaneously, the 
absolute number of older individuals is increased. Thus, the primary outcome of 
increases in life expectancy is a greater total and relative number of older persons.  
Current life expectancy is in stark contrast with the predicted lifespan of early 
Paleolithic human ancestors, who lived a mere 15-20 years in comparison (Gurven & 
Kaplan, 2007). Early increases in life expectancy followed the advent of early agriculture 
(Galor & Moav, 2007), while more recent advances can be attributed to high standards 
of living and access to advanced medical care in many areas of the world (Harper, 
2014). Life expectancy has increased at a remarkably steady rate since the mid-19th 
century, and humans have consistently lived longer than their ancestors regardless of 
social, economic, and environmental crises (Oeppen & Vaupel, 2002). Further, human 
life expectancy is predicted to increase over the next four decades (Hackett, 
Cooperman, & Ritchey, 2015). Given the current global life expectancy, and the fact that 
it is likely to continue to increase, it is wise to anticipate that the elderly demographic will 
only continue to grow.  
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Increased global life expectancy is the culmination of advances made in 
healthcare and medical science. However, a rapid increase in the size of the elderly 
population is likely to present unique societal challenges. Many healthcare-related fields 
responsible for the well-being of older individuals may be strained as the demand for 
care and treatment increases proportionally with the elderly population.  
Aging, Chronic Disease, and Disability  
Despite advances made in extending total years lived (lifespan), aging remains 
the predominant risk factor for most chronic diseases, and is associated with general 
physiological decline (Seals et al., 2016). A person’s risk for disability and chronic 
disease increases with age (Anton et al., 2015; Rowe & Kahn, 1997; Seals et al., 2016). 
Specifically, aging is the main risk factor for cancer, heart disease, stroke, diabetes, 
kidney disease, and neurodegenerative disorders such as Alzheimer’s disease and 
Parkinson’s disease (Niccoli & Partridge, 2012; Seals et al., 2016). Peripheral 
complications associated with aging, such as obesity and chronic pain, are themselves 
risk factors for chronic disease (Anton et al., 2015).  
Because aging is so strongly associated with chronic disease and disability, 
some predict an impending healthcare crisis due to such a rapid increase in the size of 
the older population (Olshansky et al., 2009; Petsko, 2008).  As the number of older 
individuals in the world increases, the number of people living with chronic disease and 
disability will increase proportionally (Olshansky et al., 2009). Even now, roughly one 
half of all adults in the US are afflicted by at least one chronic disease (Ward, Schiller, & 
Goodman, 2014), and chronic disease is the leading cause of disability (Roper et al., 
2009). Regardless of where a certain element of aging falls on the spectrum of general 
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physiological decline and full-blown disease, the current ailments associated with aging 
decrease quality of life, increases likelihood of injury, and increase the prospect that a 
person will be dependent on the care of others. 
Aging and Neurological Disorders 
Neurological disorders (ND) are an important subset of chronic diseases that 
impact the nervous system, and are often categorized by their effect on memory, 
cognitive function, and motor function. Similar to other chronic diseases, the risk for 
developing ND is extremely sensitive to increases in age (World Health Organization, 
2006). One prominent example is Alzheimer’s disease (AD), a devastating disorder that 
progressively worsens with time and primarily affects communication, judgement, and 
behavior (Alzheimer’s Association, 2017). In the United States, 10% of individuals 65 
years or older has AD, and the likelihood of having diagnosable AD increases to over 
30% once a person is 85 years old (Hebert, Weuve, Scherr, & Evans, 2013).  
As the number of elderly individuals increases, so too will the number of people 
living with ND. It is expected that by 2050 there will be nearly 1 million new cases of 
Alzheimer’s each year (Alzheimer’s Association, 2017). AD is a significant source of 
morbidity and mortality among the elderly. Those diagnosed with AD frequently need 
assistance with daily living. Eventually, AD patients become entirely dependent 
(Alzheimer’s Association, 2017), and survival rates following AD diagnosis are very low 
(Larson et al., 2004). Similarly, the number of people living with Parkinson’s disease, 
another prevalent and debilitating, age-associated ND, will have doubled between 2005 
and 2030 (Dorsey et al., 2007). 
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ND will also cause economic strain, illustrating the type of issues facing a world 
with such a large elderly population. It’s estimated that by 2050 the United States will 
spend 1 trillion dollars annually on ND (a large increase from current spending of 300 
billion) (Petsko, 2008). Given the human welfare and economic impact of the current 
and rising incidence of ND, it is imperative to develop preventative medicine and 
treatments that may delay the onset or minimize the severity of ND.  
Healthspan 
Aging has been identified as the primary risk factor for chronic disease, and 
represents a viable target for minimizing the incidence and impact of several chronic 
diseases simultaneously (Blagosklonny, 2012c; Kennedy et al., 2014; Seals et al., 
2016). In other words, an intervention that slows the aging process may prevent many 
chronic diseases at once.  Slowing aging has been a long-time goal of humanity. When 
current human life expectancy is compared to historic human life expectancy (Wilmoth, 
2000) it may appear that this goal has been accomplished. In some sense this is true, 
as most humans can expect to live considerably longer than their ancestors. However, 
most humans that do not die of accidents or acute causes experience some 
combination of physiological decline, disability, and chronic disease at the end of life 
(Bauer, Briss, Goodman, & Bowman, 2014). Thus, there is frequently a discrepancy 
between the total number of years a person lives (lifespan) and the number of years a 
person lives free from the burden of chronic disease and disability (healthspan).  
The concept of healthspan has recently become a prominent feature of aging 
research (Kaeberlein, Rabinovitch, & Martin, 2015; Seals et al., 2016), and is the focus 
of a new field of aging research known as geroscience (Kennedy et al., 2014). In 
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general, the duration of healthspan is shorter than that of lifespan, and the end of 
healthspan is marked by the onset of disability and chronic disease. It has been 
proposed that the primary goal of aging research should be to increase the duration of 
healthspan, or to minimize the amount of time a person spends in physiological decline 
(Anton et al., 2015; Kennedy et al., 2014; Seals et al., 2016). Aging research should be 
conducted with the primary goal of improving health through minimizing or slowing the 
aging process, rather than simply extending the total number of years lived regardless 
of health status.  
Conventionally, chronic disease research has focused on either the prevention of 
specific diseases, or treatment of individual symptoms once disease is established. 
Take, for example, the recommendation of sunscreen use to prevent cancer (Green, 
Williams, Logan, & Strutton, 2011), or the prescription of insulin to treat type 2 diabetes 
(Charbonnel, Penfornis, Varroud-Vial, Kusnik-Joinville, & Detournay, 2012). In these 
cases and others, this approach is relatively effective. However, the continually high 
prevalence of disability and chronic disease, particularly among the elderly, illustrates 
the shortcomings of utilizing such a narrow approach. If aging is the primary risk factor 
for many chronic diseases and disability, then the biology of aging is a suitable target for 
addressing many chronic diseases simultaneously. Thus, targeting aging is preferable 
to a single disease focus for chronic disease prevention. Increasing healthspan by 
slowing the aging process will prevent general age-associated physiological decline, 




Theoretical Causes of Aging  
For some time, aging was thought to be the consequence of accumulated and 
irreversible molecular and macromolecular damage, caused primarily by reactive 
oxygen species (ROS) (Anson & Bohr, 2000; Beckman & Ames, 1998; Harman, 1956). 
Recently, it has become apparent that damage accumulation likely represents only part 
of the aging process,  (Bjelakovic, Nikolova, Gluud, Simonetti, & Gluud, 2007; Doonan 
et al., 2008; Speakman & Selman, 2011) as treatments that reduced oxidative damage 
failed to extend lifespan in model organisms (Bjelakovic et al., 2007; Doonan et al., 
2008; Pérez et al., 2009). Additional studies revealed that long-lived organisms do not 
necessarily possess increased protection against destructive ROS (Andziak, O’Connor, 
& Buffenstein, 2005; Bjelakovic et al., 2007; Voituron, de Fraipont, Issartel, Guillaume, & 
Clobert, 2011), and that impairing antioxidant defense systems does not shorten 
lifespan (Huang, Carlson, Gillespie, Shi, & Epstein, 2000; Pérez et al., 2009; Van 
Raamsdonk & Hekimi, 2009; W. Yang, Li, & Hekimi, 2007). It is true that markers of 
oxidative damage increase with aging and molecular damage has a role in age-
associated physiological decline (Forster et al., 1996; Sohal, Agarwal, Dubey, & Orr, 
1993). However, it appears that either molecular damage is merely a component of 
aging (Kennedy et al., 2014; Salmon, Richardson, & Pérez, 2010), or that a more 
sophisticated understanding of redox biology is required to fully appreciate its causal 
role in the aging process (Halliwell, 2012; Murphy et al., 2011). 
At the same time, it has been demonstrated that the activity of highly conserved 
cellular signaling pathways also contributes to aging (Blagosklonny, 2008; M. 
Kaeberlein et al., 2005; Kapahi et al., 2010). Manipulation (both directly and indirectly) 
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of various processes involved in growth and responses to nutrient intake consistently 
extend lifespan and improve health outcomes in a diverse range of species, ranging 
from single-celled organisms to non-human primates (Blagosklonny, 2006). The 
existence of specific and conserved signaling cascades that directly regulate aging 
suggests that aging is a coordinated and programmed process, similar to those that 
regulate development and organismal function. However, considered in the context of 
evolution this theory also loses credibility. A synchronized process that serves only to 
promote physiological decline and increase susceptibility to disease would not be 
maintained through natural selection (Blagosklonny, 2007; Kirkwood, 2005; Williams, 
1957). Additionally, humans surviving into what is currently considered “old age” is a 
very recent phenomenon on the timescale of human evolution (Gurven & Kaplan, 2007; 
Oeppen & Vaupel, 2002). The likelihood of natural selection to have the potential to 
select for genes that act only in “old age” is therefore extremely low (Kirkwood, 2005; 
Williams, 1957).  
Evolutionary theory then eliminates the possibility of a direct, programmed cause 
of aging. This conclusion is problematic, however, as it is in conflict with the repeated 
observation that identifiable genes and molecular signaling pathways regulate longevity. 
As mentioned, the cellular networks that regulate aging are also necessary for 
developmental growth, as well as responses to nutrient intake (Gangloff et al., 2004; 
Kapahi et al., 2010). Commonalities between these two processes indicate that 
organismal growth and aging share a common mechanism. Based on this idea, it has 
been hypothesized that aging is not necessarily programmed, but is simply the 
inappropriate and unnecessary continuation of growth and development when they are 
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no longer needed (Blagosklonny, 2006, 2010; Gems & de la Guardia, 2013). Thus, 
aging may be “quasi-programmed” in that it is the needless activation of cellular 
programs that otherwise serve necessary purposes.  
In the quasi-programmed, or “hyperfunction”, model of aging organismal 
senescence is caused by processes that promote growth during development but do not 
cease when growth is no longer necessary (Blagosklonny, 2007, 2010; Gems & de la 
Guardia, 2013). Continuation of these processes leads to cellular and organismal 
hyperfunction, which is a detriment to the cell and eventually the organism 
(Blagosklonny, 2012b, 2013a). This model is appealing because it appears to be well 
supported experimentally. Treatments that slow growth or decrease the activity of 
cellular mechanisms that contribute to growth improve health outcomes and extend 
lifespan with remarkable consistency (Kaeberlein et al., 2005; Kapahi et al., 2004a; 
Selman et al., 2009). Additionally, unlike theories of programmed aging, the “quasi-
programmed” theory of aging is feasible in the context of evolution. Until very recently, 
humans did not live into old age due to acute causes of death. In a scenario where 
humans do survive into old age, there is no selective pressure to inhibit processes that 
beneficially promote growth early in life, but eventually cause aging late in life 
(Blagosklonny, 2007).  
That hyperfunction precedes age-related physiological decline can be observed 
in many age-related chronic diseases (Tsang, Qi, Liu, & Zheng, 2007). For example, 
hyperactivity of cells that secrete cytokines causes inflammation, a hallmark of aging 
(Kennedy et al., 2014) and ubiquitous characteristic of chronic disease (Hunter, 2012). 
Cancer also provides an example of hyperfunction resulting in dysfunction which 
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contributes to chronic disease. It is true that cancer can arise from genetic mutations 
caused by damage (Valko, Izakovic, Mazur, Rhodes, & Telser, 2004). However, DNA 
damage in itself is not sufficient for cancer, and cancer does not occur unless genetic 
damage somehow causes dysregulation of cell growth and proliferation (Guertin & 
Sabatini, 2005; Vogelstein & Kinzler, 2004). 
Although the hyperfunction model of aging addresses inconsistencies that arise 
in some theories of aging, it is not without its own limitations. For example, many age-
associated disease, such as sarcopenia (Brooks & Faulkner, 1994) and Alzheimer’s 
disease (de la Monte, 1989; Swaab, Hofman, Lucassen, Salehi, & Uylings, 1994), are 
associated with cell atrophy, which is in conflict with the idea that it is cell growth and 
proliferation that underlies aging. Proponents of the hyperfunction model of aging may 
contest that some form of hyperactivity precedes such atrophy (Blagosklonny, 2012a). It 
has been argued that if hypertrophy and hyperactivity are vaguely defined, nearly 
physiological characteristic can be attributed to them, and that the generation of 
damage inducing-ROS is in fact due to cellular hyperactivity (Zimniak, 2012).  
The disposable soma theory of aging posits that energetic resources are 
allocated in a way that either promotes growth and reproduction, or favors conditions of 
maintenance and repair (Kirkwood & Holliday, 1979; Kirkwood, 2005). The basis of the 
disposable soma theory is that in the wild, the soma need be maintained only as long as 
an organism has a realistic chance of surviving and reproducing (Kirkwood & Austad, 
2000). Under favorable energetic conditions, processes that promote reproduction will 
be favored over those which would slow aging through cellular and tissue maintenance 
and repair (termed “somatic maintenance”). From an evolutionary standpoint, 
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maintenance and repair (which contribute longevity of the individual) is of less 
importance than the passing of genetic material to future generations, especially when 
the probability of extrinsic mortality is high (Kirkwood & Rose, 1991). In the wild, the 
benefit of investing in maintenance and repair is outweighed by the benefit of investing 
in short-term survival and reproduction. The disposable soma theory is supported by 
studies showing that reproduction is inversely related to survival in humans (Tabatabaie 
et al., 2011) and that the elimination of the germ line extends lifespan in some (Berman 
& Kenyon, 2006; Hsin & Kenyon, 1999), but not all (Barnes, Boone, Jacobson, 
Partridge, & Chapman, 2006), model organisms tested.  
One possible reconciliation of the discrepancies in each of the theories of aging 
is that no theory is mutually exclusive from another. One characteristic that is constant 
in each of the aforementioned theories of aging is that biological imperfections 
accumulate with time and impair cell and organismal function. It has been proposed that 
aging arises from a combination of both random and intrinsic processes. These 
imperfections constitute the “deleteriome”, which encompasses damage (in its classical 
sense) and all detrimental processes initiated by genetics and cell signaling (Gladyshev, 
2016). Over time, the deleteriome grows in both its size and effect on the organism, 
which gradually results in aging. The deleteriome model of aging offers a potential 
compromise between molecular damage and cell signaling pathway-based theories of 
aging.  
Clearly, aging is complex and much remains to be learned about its underlying 
causes. Although there is no consensus on any single factor that is the proximal cause 
of aging, long-lived model organisms and treatments that extend lifespan can be used 
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to study the impact of various biological processes and factors that may contribute to 
the aging process. Experimental models of slowed aging can be used in laboratory 
settings to help better understand why we age and how the rate of aging can be altered. 
Models of Slowed Aging 
A variety of experimental interventions known as slowed aging treatments act on 
growth-inducing and nutrient-sensing pathways to extend lifespan and improve health. 
The link between growth and aging is readily observed in the case of caloric restriction 
(CR), or decreased caloric intake without causing malnutrition. CR is the most well-
established (Heilbronn & Ravussin, 2003; Masoro, 2003, Masoro 2005) and long-known 
(Osborne, Mendel, & Ferry, 1917) longevity-promoting experimental intervention. CR 
improves survival and health outcomes in a wide range of species, from single-celled 
budding yeast to non-human primates (Bodkin, Alexander, Ortmeyer, Johnson, & 
Hansen, 2003; R. J. Colman et al., 2009; Ricki J. Colman et al., 2014; Mattison et al., 
2012). Even upon its discovery a century ago, the lifespan extending effects of CR were 
correctly (if indirectly) associated with its effect on growth (Osborne et al., 1917).  
Recently, slowed aging treatments that utilize genetic manipulation have also 
proven to be indispensable for investigating the mechanisms that underlie aging and 
how they can be targeted (Blagosklonny, 2009). Similar to CR, many of these 
manipulations involve pathways related to nutrient sensing and growth. Ames and Snell 
dwarf mice lack growth hormone signaling, and are both long-lived (Bartke et al., 2001; 
Bartke, 2006; Brown-Borg, Borg, Meliska, & Bartke, 1996; Miller, 1999). A wide range of 
animals genetically engineered to be deficient in various components of the 
insulin/insulin-like growth factors signaling axis (IIS) are long-lived (Kenyon, 2010; van 
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Heemst, 2010), including Drosophila melanogaster (Tatar et al., 2001), Caenorhbaditis. 
Elegans (Friedman & Johnson, 1988), and Mus Musculus (Selman et al., 2007). 
Reductions in IIS have also been proposed to play a role in longevity in humans 
(Kenyon, 2010). 
In addition, certain pharmaceutical compounds have become prominent players 
in aging research as potent slowed aging treatments. The immunosuppressant, 
rapamycin (also known as siromilus) is one such compound (Ehninger, Neff, & Xie, 
2014; Harrison et al., 2009). Currently, the anti-diabetic drug Metformin is the topic of 
extensive study in aging research (Anisimov, 2010, 2013; Anisimov et al., 2008b). As 
will be discussed further, both have been shown to extend lifespan and improve health 
in a diverse array of species including humans.  
Each slowed aging intervention provides unique insight to the aging process. 
Identification, understanding, and refinement of these treatments is essential to 
understanding aging so that eventually it may be slowed. It should be a high priority to 
identify common underlying mechanisms that link each of these treatments together.  
Molecular Mechanisms of Aging 
Many experimental treatments that extend lifespan mimic or induce growth 
restriction. This shared characteristic opens the possibility that multiple slowed aging 
treatments, although unique in nature, converge on a single physiological element. 
Much research suggests that this is may be the case. At the nexus of each the 
aforementioned lifespan extension treatments is the conserved serine/threonine kinase, 
mechanistic target of rapamycin (mTOR) (Kapahi et al., 2010). mTOR lies downstream 
to a variety of growth-promoting pathways, such as the insulin/insulin-like growth factor 
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signaling axis (IIS) and the growth hormone signaling axis (Laplante & Sabatini, 2009). 
Additionally, mTOR is sensitive to cellular energy status and responds to changes in 
cellular AMP/ATP levels through inhibition by 5’ adenosine monophosphate-activated 
protein kinase (AMPK) (Inoki, Zhu, & Guan, 2003). mTOR also acts as a direct nutrient 
sensor and is stimulated by amino acids (Nobukuni et al., 2005).  
In a general sense, mTOR is a ubiquitous anabolic promoter, inducing cell 
growth and proliferation in response to nutrients and growth factor binding (Kim, Buel, & 
Blenis, 2013). One of the primary roles of mTOR is as a key regulator of protein 
synthesis, primarily through translation initiation, elongation, and ribosomal biogenesis 
(Kapahi et al., 2010). mTOR also regulates lipid biosynthesis to promote cell division, 
inhibits catabolic processes (mainly autophagy), and promotes progression through the 
cell cycle (Fingar et al., 2004; Laplante & Sabatini, 2009). Under the proper 
circumstances, cell growth and division induced by mTOR are necessary components 
of healthy cell and organismal function and development. The importance of mTOR 
during development is demonstrated by studies which show that mTOR knockouts are 
embryonic lethal (Guertin et al., 2006; Murakami et al., 2004). That reducing the 
sources of input to mTOR results in lifespan extension, coupled with the fact that mTOR 
is a crucial regulator of growth and development, implicates mTOR as a possible 
mechanistic link between nutrient intake/status, growth, and aging (Johnson, 
Rabinovitch, & Kaeberlein, 2013). 
The notion that mTOR connects nutrient intake, growth, and aging is supported 
by a growing body of research that shows inhibition of mTOR, directly or indirectly, 
extends lifespan. In Saccharomyces cerevisiae, deletion of genes involved in the mTOR 
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pathway extends lifespan (Kaeberlein et al., 2005; Powers, Kaeberlein, Caldwell, 
Kennedy, & Fields, 2006). The use of RNA interference in C. elegans has demonstrated 
that deficiency in mTOR signaling is sufficient for lifespan extension (Vellai et al., 2003), 
and mTOR is involved in IIS-regulated lifespan extension (K. Jia, Chen, & Riddle, 2004). 
In D. melanogaster, decreased activity of both upstream and downstream components 
of mTOR by genetic manipulation results in increased lifespan (Kapahi et al., 2004b). 
Overexpression of tuberous sclerosis complex, a primary negative regulator of mTOR, 
improves a number of health outcomes and extends lifespan in mice (Zhang, Diaz, 
Walsh, & Zhang, 2017). In the long-lived Ames dwarf mice, mTOR signaling is 
significantly reduced (Sharp & Bartke, 2005). Additionally, deletion of ribosomal protein 
s6 kinase (S6K), one of two primary effectors of mTOR that promotes translation, is 
sufficient for lifespan extension in mice (Selman et al., 2009).  
Although mTOR activity appears to have an important role in longevity, it cannot 
explain all models of slowed aging. However, not all models of slowed aging 
demonstrate decreased mTOR signaling, and modification of mTOR signaling is not 
always required for lifespan extension. Caloric restriction during suckling by increasing 
litter size in (crowded litter, CL) increases lifespan (Sadagurski et al., 2014). In CL mice 
mTOR signaling is unaffected at 4 months and increased at 7 months of age (Drake et 
al., 2014). Additionally, restriction of dietary methionine promotes longevity without 
altering mTOR signaling (Sun, Sadighi Akha, Miller, & Harper, 2009), and branched-
chain amino acid supplementation extends lifespan despite increases in mTOR 
substrate activation (D’Antona et al., 2010).  
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Clearly, mTOR signaling is a key piece of the aging puzzle. Repeatedly, 
modulations in mTOR signaling extend lifespan in model organisms, and decreased 
activity through the mTOR pathway is a common feature of models of slowed aging. 
Despite that mTOR inhibition is not necessary in all models of slowed aging, the 
growing body of literature on mTOR-mediated lifespan extension warrants further 
investigation.  
Regulation of Aging by mTOR 
Decreased activity through the mTOR signaling pathway, either directly or 
indirectly, improves health and increases lifespan in many model organisms. Signaling 
through the mTOR pathway is required for development and mTOR knockouts are not 
viable (Guertin et al., 2006; Murakami et al., 2004). However, reductions in mTOR 
activity underlie lifespan extension in various models of slowed aging, including 
impaired IIS (K. Jia et al., 2004) and caloric restriction (Kaeberlein et al., 2005). 
Additionally, genetic inhibition of the mTOR signaling pathway is sufficient for lifespan 
extension (Selman et al., 2009). That mTOR activity is required for development, and its 
inhibition promotes longevity seems paradoxical. This raises the question of how mTOR 
regulates lifespan extension. The general role of mTOR is to induce cell growth and 
proliferation in response to nutrients, growth factors, and high energy status (Fingar et 
al., 2004; Laplante & Sabatini, 2009). In regard to aging, it appears that mTOR 
regulates the aging process primarily through protein synthesis, protein catabolism 
(autophagy), responses to stress, and alterations in metabolism (Kapahi et al., 2010).  
In some cases, inhibition of translation is sufficient for lifespan extension. mTOR 
stimulates protein synthesis by phosphorylation of its downstream effectors, eukaryotic 
 19 
initiation factor eIF4E-binding protein (4E-BP) and S6K (Kapahi et al., 2010). Reducing 
translational rates by decreasing 4E-BP, S6K, or ribosomal proteins extends lifespan in 
C. elegans (Hansen et al., 2007), as does direct inhibition of translation (Pan et al., 
2007). This finding has been repeated in other model organisms (M. Kaeberlein et al., 
2005; Kapahi et al., 2004b; Selman et al., 2009; Steffen et al., 2008). The translational 
repressor, 4E-BP, is required for CR induced lifespan extension (Zid et al., 2009). 
Constitutively active 4E-BP extends lifespan as well, which is not furthered by CR (Zid 
et al., 2009). Additionally, protein synthesis negatively corresponds with lifespan 
(Katewa & Kapahi, 2011). Although reduced rates of protein synthesis may be important 
for mTOR-mediated lifespan extension, none of the aforementioned studies measured 
the effects of cell proliferation, which may be the primary, or an additional, mechanism 
by with mTOR inhibition extends lifespan.  
Autophagy is one of two primary means of protein degradation in the cell and 
acts as a clearance mechanism of cellular damage. mTOR inhibits autophagy (Jung, 
Ro, Cao, Otto, & Kim, 2010), and increased autophagic activity has been strongly 
implicated in longevity (Madeo, Tavernarakis, & Kroemer, 2010; Petrovski & Das, 2010). 
In C. elegans, autophagy is necessary for CR to increase lifespan (Hansen et al., 2008), 
and inhibition of translation of autophagic proteins shortens lifespan (Hars et al., 2007). 
In addition to its effect on protein synthesis and degradation, mTOR is also 
involved in cellular stress resistance. Pharmacological inhibition of mTOR in both C. 
elegans and M. muluscus activates endogenous xenobiotic defense systems, regulated 
by SKN-1 and NRF2, respectively (Robida-Stubbs et al., 2012; Steinbaugh, Sun, 
Bartke, & Miller, 2012). Despite large-scale decreases in protein translation following 
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mTOR inhibition (X. M. Ma & Blenis, 2009), certain nuclear-encoded mitochondrial 
proteins maintain translational rates (Zid et al., 2009), and the function of these 
mitochondrial proteins is required for CR-induced lifespan extension. Mitochondrial 
protein synthesis may reflect increased or maintained oxidative capacity during CR, 
which could ensure adequate ATP stores for energetically costly but beneficial 
processes (Zid et al., 2009), such as protein turnover. Additionally, CR-induced 
mitochondrial biogenesis is associated with increased mitochondrial efficiency and 
lower ROS production (López-Lluch et al., 2006), adding a further layer of stress 
resistance attributable to mTOR inhibition. 
Slowed Aging Tools - Rapamycin and Metformin 
The pharmaceuticals, rapamycin and metformin, are among the growing list of 
slowed aging treatments garnering much attention in the field of geroscience. Each 
serves as a valuable tool for investigating the mechanisms of aging and effects of 
slowed aging treatments. Originally isolated as a macrolide antibiotic from the bacteria, 
Streptomyces hygroscopicus, rapamycin was discovered in soil obtained from the island 
of Rapa Nui (Vézina, Kudelski, & Sehgal, 1975). Rapamycin has conventionally been 
prescribed to prevent organ rejection following transplantation (Groth et al., 1999), and 
to treat various forms of cancer (Seto, 2012). In model organisms, rapamycin extends 
lifespan and improves a multitude of health outcomes.  
In 2009, rapamycin became the first compound to extend lifespan in both sexes 
of a mammalian species (Harrison et al., 2009). A multi-site study conducted through 
the National Institute on Aging’s Intervention Testing Program (ITP) showed that 
consumption of rapamycin significantly extended median and maximal lifespan in both 
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male and female genetically heterogeneous mice (Harrison et al., 2009). Importantly, 
lifespan extension was observed when rapamycin was administered late in adult life 
(600 day-old mice, roughly the equivalent of 60 year-old humans), showing that lifespan 
extending treatments may be effective even when initiated in old age.  
Additionally, the relative contributions of age-related causes of death were not 
different between rapamycin-treated and control mice, suggesting that the increase in 
lifespan indicates slowed aging, rather than the prevention of any single disease 
(Harrison et al., 2009). That rapamycin improves certain health outcomes, in addition to 
extending lifespan, has been shown repeatedly. In mice, rapamycin prevents age-
associated macular degeneration (Kolosova et al., 2012), increases in obesity (S.-B. 
Yang et al., 2012), decreased cognitive function (Halloran et al., 2012), liver 
degeneration (Wilkinson et al., 2012), declines in physical activity and strength 
(Wilkinson et al., 2012; Xue et al., 2016), arterial stiffness (Lesniewski et al., 2017), and 
tumorigenesis in mice genetically predisposed to cancer (Komarova et al., 2012). The 
results of a comprehensive study on the effect of rapamycin on healthspan and aging 
appeared to suggest that the effect of rapamycin-mediated lifespan extension was 
primarily due to the prevention of cancer (Neff et al., 2013). However, this conclusion 
has been contested as a misinterpretation (Blagosklonny, 2013b; Johnson, Martin, 
Rabinovitch, & Kaeberlein, 2013). Further, rapamycin extends lifespan in organisms that 
do not develop cancer (Bjedov et al., 2010; Powers et al., 2006; Robida-Stubbs et al., 
2012) 
Metformin is widely prescribed to improve insulin sensitivity for treatment of type 
2 diabetes (T2D). Metformin has also been suggested as a feasible slowed aging 
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treatment for use in humans (Barzilai, Crandall, Kritchevsky, & Espeland, 2016). The 
use of metformin to slow aging in the general population is the primary focus of the 
recently proposed, large-scale clinical trial, “TAME” (Targeting Aging with MEtformin) 
(Barzilai et al., 2016), which would represent the first clinical trial of a drug intended to 
slowing aging and increase the duration of healthspan. 
In both model organisms and humans, metformin appears to induce a variety of 
protective effects. In nematode worms, metformin mimics the effects of CR and 
increases healthspan (Onken & Driscoll, 2010). In mice, metformin decreases body 
weight and extends both median and average lifespan (Anisimov et al., 2008; Martin-
Montalvo et al., 2013), although the direct effect of metformin on lifespan in rodents is 
somewhat inconsistent (Strong et al., 2016). Metformin improves measurements of 
cognitive function in older mice, in addition to increasing lean body mass and protecting 
against fat accumulation in the face of high fat diet (Allard et al., 2016). In individuals 
diagnosed with T2D, metformin may decrease risk for atherosclerosis (Goldberg et al., 
2017) and cardiovascular disease (UK Prospective Diabetes Study Group, 1998). 
Results from the United Kingdom Prospective Diabetes Study demonstrated that 
metformin decreased diabetes-related mortality by 42%, and all cause-mortality was 
decreased by 36% in those taking metformin (UK Prospective Diabetes Study Group, 
1998). Epidemiological data suggests that not only do type 2 diabetics who are 
prescribed metformin live longer than those prescribed other common antidiabetic 
drugs, they may even surpass their nondiabetic counterparts in survival (Bannister et 
al., 2014).  
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The apparent efficacy and relative safety of both rapamycin and metformin as 
slowed aging treatments begs the question of why each or both is not currently used for 
widespread disease prevention in humans. In large part, this is due to a lack of clinical 
trials for either as slowed aging tools. The absence of a clear, clinical definition of aging 
contributes to inconsistencies in opinion of how aging should be targeted, and limits 
progress in developing anti-aging clinical trials (Barzilai et al., 2016). Additionally, 
although rapamycin extends lifespan and is beneficial to many aspects of health, 
chronic rapamycin treatment has negative side effects, including testicular degeneration 
and cataracts in mice (Wilkinson et al., 2012). Similarly, chronic rapamycin treatment 
impairs glucose homeostasis by decreasing hepatic insulin sensitivity (Lamming et al., 
2012). Based on this, intermittent treatment of rapamycin has been proposed to 
potentially negate these effects, and in limited testing of intermittent treatment has 
shown be effective (Anisimov et al., 2011; Arriola Apelo, Pumper, Baar, Cummings, & 
Lamming, 2016). Finally, co-treatment with metformin may offset the impaired glucose 
tolerance associated with rapamycin (Aliper et al., 2017; Blagosklonny, 2017), and this 
approach may demonstrate additive effects of both drugs on healthspan.  
Modification of Signaling Pathways by Rapamycin and Metformin  
mTOR was discovered during exploration of the anti-growth properties of 
rapamycin, for which the protein kinase is named (Heitman, Movva, & Hall, 1991). Upon 
testing it was revealed that rapamycin-induced growth inhibition is mediated by a protein 
(or several proteins, in yeast) deemed target of rapamycin (and subsequently, 
mechanistic target of rapamycin) (Heitman et al., 1991). Rapamycin is a direct and 
potent inhibitor of mTOR. The primary mechanism by which rapamycin inhibits mTOR is 
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through allosteric inhibition. Rapamycin binds 12-kDa FK506-binding protein (FKBP12), 
which inhibits the assembly of mTOR complex 1 (mTORC1) (Laplante & Sabatini, 
2009). The main action of mTORC1 is to regulate cell growth and division (Fingar et al., 
2004). mTOR forms a second complex, (mTORC2) that regulates cytoskeletal 
organization and dynamics and is rapamycin-insensitive (Jacinto et al., 2004). However, 
chronic administration of rapamycin affects both mTOR complexes, and inhibition of 
mTORC2 contributes to rapamycin-induced hepatic insulin resistance (Lamming et al., 
2012).  
 Although the exact molecular mechanism of metformin remains unclear (Rena, 
Hardie, & Pearson, 2017), it is currently thought that the beneficial effects of metformin 
are stimulated by activation of AMPK (Zhou et al., 2001). A widely accepted explanation 
of this effect is that metformin inhibits complex I of the electron transport chain, 
increasing the ratio of cellular AMP:ATP, thereby activating AMPK (El-Mir et al., 2000; 
Owen, Doran, & Halestrap, 2000). However, AMPK activation may not be required for 
the insulin sensitizing effects of metformin (Foretz et al., 2010; Guigas et al., 2006). 
Activated AMPK inhibits mTOR (Xu, Ji, & Yan, 2012). Specifically, AMPK targets 
tuberous sclerosis complex 2, which forms a complex with tuberous sclerosis complex 1 
to inhibit the formation of mTORC1 (Howell et al., 2017a; Inoki et al., 2003). 
Additionally, AMPK phosphorylates the mTOR binding protein, raptor, further preventing 
the formation of mTORC1 (Gwinn et al., 2008). In this way, both rapamycin and 
metformin inhibit the growth and proliferative effects of mTOR, potentially explaining 
their effect on lifespan and health.  
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Rapamycin and Metformin in the Brain 
The rise to prominence of metformin and rapamycin in aging research has 
sparked investigation into the effect of each on the central nervous system. Although 
most research has focused on the effect of rapamycin and metformin in peripheral 
tissues, each crosses the blood brain barrier (Halloran et al., 2012; Łabuzek et al., 
2010; Meikle et al., 2008) and may affect the central nervous system. In mice, 
rapamycin reduces age-associated decreases in physical activity (Miller et al., 2011; 
Neff et al., 2013; Wilkinson et al., 2012) and improves performance in tasks involving 
learning and memory (Neff et al., 2013). Near lifelong treatment of rapamycin improves 
cognitive function in older mice and may be related to decreases in brain inflammation 
(Majumder et al., 2012). One comprehensive study replicated findings that rapamycin 
treatment improves spatial learning and memory in both young and old mice (Halloran 
et al., 2012). It was also revealed that rapamycin increased the levels of the 
neurotransmitters; norepinephrine, dopamine, and 5-hydroxytryptamine, in conjunction 
with apparent decreased anxiety and depressive-like behavior (Halloran et al., 2012b).  
Recently, rapamycin has been proposed as a treatment for multiple forms of ND 
(Bové, Martínez-Vicente, & Vila, 2011). Rapamycin is thought to be neuroprotective, in 
part, through induction of autophagic processes (Cai & Yan, 2013; Jahrling & Laberge, 
2015). In transgenic mouse models of AD, rapamycin improves cognitive function, 
promotes autophagy, and reduces the levels of amyloid-B (AB) (Spilman et al., 2010). 
Similarly, there is strong evidence for the role of mTOR in tau hyperphosphorylation, a 
potential contributor to AD (Gong & Iqbal, 2008). Rapamycin prevents this process and 
restores normal cognitive function (Caccamo et al., 2013). Neuroprotection has been 
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observed using rapamycin and a rapamycin ester in Drosophila and mouse models of 
Huntington’s disease, respectively (Ravikumar et al., 2004). Additionally, rapamycin 
prevents loss of cognitive function in a mouse model of Parkinson’s disease by restoring 
mitochondrial homeostasis via induction of mitophagy (Siddiqui et al., 2015).  
Although much research is still needed, metformin represents another potential 
treatment in chronic neurodegenerative disorders (Markowicz-Piasecka et al., 2017). 
Metformin appears to elicit similar effects in the brain as in peripheral tissue, such as 
AMPK activation and subsequent increases in autophagy (Jiang et al., 2014). Metformin 
extends lifespan of male mice by 20% in a transgenic model of Huntington’s disease in 
a dose-dependent manner (Ma et al., 2007). Type 2 diabetics are at increased risk for 
AD, and T2D can speed the rate of cognitive decline (Ascher-Svanum et al., 2015; 
Luchsinger, Tang, Shea, & Mayeux, 2004). The effect of T2D on cognitive function 
appears to be reduced by metformin treatment (Cheng et al., 2014). Interestingly, the 
apparent neuroprotection offered by metformin in those with T2D is dependent on the 
duration of treatment, and not observed following treatment of all types of antidiabetic 
medication. Mice subjected to AB show decreased long-term potentiation, a neural 
adaptation process that is the basis of synaptic plasticity and memory. Metformin 
attenuates this decrease, suggesting neuroprotective effects and implicating metformin 
as a potential treatment for AD (Asadbegi, Yaghmaei, Salehi, Ebrahim-Habibi, & 
Komaki, 2016). Additionally, metformin increases neuronal insulin sensitivity, a process 
which reverses AD-like characteristics of hyperglycemia-exposed neuronal cells (Gupta, 
Bisht, & Dey, 2011). However, one study found that treatment with metformin increases 
AB production in vitro (Chen et al., 2009). Co-treatment with insulin reversed this effect 
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and lowered AB biogenesis overall (Chen et al., 2009), suggesting that a combination of 
metformin and insulin may protect against AD. This is congruent with epidemiological 
research that has demonstrated protection against AD in type 2 diabetics when insulin 
and metformin are taken together (Beeri et al., 2008). 
Neurodegenerative diseases are commonly associated with protein aggregation 
(Eftekharzadeh et al., 2016). Although some research is conflicting, it appears that both 
rapamycin and metformin offer neuroprotection under certain conditions. Given the 
effect of rapamycin and metformin on both protein synthesis and breakdown, it is 
possible that the primary means by which both rapamycin and metformin maintain or 
promote neuronal function is through preservation of the proteome.  
Proteostasis 
Protein homeostasis, or proteostasis, refers to the collective processes that 
maintain protein concentration, location, and conformation (Balch et al., 2008). 
Maintenance of the proteome (proteostatic maintenance) is accomplished by an 
extraordinarily complex and coordinated system known as the “proteostasis network” 
(PN), which can be divided into three broad branches; protein translation (synthesis), 
degradation, and folding (Klaips, Jayaraj, & Hartl, 2018). The cyclical process of protein 
synthesis and degradation is often referred to as protein turnover (Hinkson & Elias, 
2011). Protein turnover is a crucial cell, tissue, and organismal function. Loss of 
proteostasis is characteristic of many chronic diseases as well as aging (Cohen & Kelly, 





As discussed, protein synthesis is largely under the control of mTORC1, and is 
regulated by a wide variety of factors including energy status, growth factor signaling, 
mechanostransduction, hypoxia, and nutrients (Laplante & Sabatini, 2009; X. Wang & 
Proud, 2006). Protein synthesis is a critical component of cell function and proteostatic 
maintenance, determining many important characteristics of the proteome (Arnsburg & 
Kirstein-Miles, 2014). Protein synthesis is required for the cell growth and division 
(Polymenis & Aramayo, 2015), as well as adaptations to stress and hormesis (Holcik & 
Sonenberg, 2005; Radak, Chung, Koltai, Taylor, & Goto, 2008; Rogers et al., 2011), a 
concept that has implications for health and aging. For example, in response to 
energetic stress (such as in CR and exercise), low cellular ATP levels stimulate the 
synthesis of mitochondrial proteins (Hood, 2009; Miller, Robinson, Bruss, Hellerstein, & 
Hamilton, 2012; Zid et al., 2009), an outcome that better equips the cell and organism to 
handle energetic stress in the future.  
Protein Folding 
In order to properly function, proteins must contain the correct sequence of 
amino acids. However, the appropriate amino acid sequence alone is not sufficient for 
protein function, and proteins must be folded into highly specific 3-dimensional 
structures known as conformations. Following translation, proteins spontaneously adapt 
a partially folded state due to the loss of free energy associated with intramolecular 
bonding within a polypeptide (Onuchic & Wolynes, 2004). Mechanisms that aid in 
protein folding are necessary, as spontaneous folding is error prone (Schubert et al., 
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2000), and proteins must be refolded following oxidative damage (Wickner, Maurizi, & 
Gottesman, 1999).  
Because of the importance of protein folding, cellular machinery exists solely for 
the purpose of ensuring adequate protein folding. The heat shock protein family (HSP) 
and chaperonins are molecular protein folding aids (Klaips et al., 2018). Heat shock 
proteins recognize hydrophobic amino acid sequences that become exposed upon 
misfolding (Rüdiger, Buchberger, & Bukau, 1997), and promote the correct 
conformation utilizing ATP hydrolysis (Clerico, Tilitsky, Meng, & Gierasch, 2015). If the 
HSP system is not successful in folding a protein, it may be transferred to a number of 
chaperonins (Lopez, Dalton, & Frydman, 2015), adding another layer of regulation for 
protein folding.  
Protein Degradation 
 If protein folding mechanisms fail, misfolded and damaged proteins must be 
degraded to avoid their accumulation. This process is essential, as the accumulation of 
damaged proteins and protein aggregates is toxic to cells (Morimoto, 2008). 
Additionally, protein degradation is essential for cell and tissue remodeling (Mizushima 
& Komatsu, 2011). Breakdown of proteins generally occurs through one of two 
mechanisms; autophagy and proteosomal degradation (Mizushima & Klionsky, 2007; 
Mortimore & Poso, 1987; Poppek & Grune, 2006). Proteosomal degradation tends to 
target individual proteins, whereas autophagic processes are better equipped for large 
protein aggregates and whole organelles. Protein degradative processes are essential, 
as the enzymatic capacity for protein repair is low (Mary et al., 2004). Thus, the primary 
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means of protein “repair” is through degradation and re-synthesis (Mary et al., 2004; 
Mortimore & Poso, 1987).  
 Maintenance of the proteome is accomplished by a wide range of complex and 
highly coordinated processes. Given the necessity of appropriate protein concentration 
and function, it is difficult to overstate the importance of proteostatic maintenance in 
health and disease, as well as slowed aging.  
Proteostasis and Slowed Aging 
Recently, proteostasis was identified as one of the seven pillars of aging 
(Kennedy et al., 2014). Loss of proteostasis is thought to be a major contributor to both 
aging and age-related disease (Kaushik & Cuervo, 2015; Labbadia & Morimoto, 2015b; 
López-Otín et al., 2013). Thus, proteostasis is a target for slowed aging treatments and 
the prevention of chronic disease (Balch et al., 2008). As discussed, a simplified view of 
the PN is that it is comprised of cellular machinery responsible for protein synthesis, 
folding and refolding, as well as degradation. Importantly, each branch of the PN is 
compromised with aging. 
Protein translation decreases with age (Rattan, 1996), and in age-related chronic 
disease (Proctor, Balagopal, & Nair, 1998; K. L. Smith & Tisdale, 1993). This is 
somewhat paradoxical as treatments that inhibit translation prolong lifespan (Hansen et 
al., 2007). Some have speculated that reduced translation may lessen the burden of the 
other components of the PN, thus promoting proteostatic maintenance (Taylor & Dillin, 
2011; Walter & Ron, 2011). Additionally, decreased protein synthesis is associated with 
decreased rates of cell proliferation, which may indicate preferential synthesis of 
proteins for proteostatic maintenance (Miller et al., 2012). Indeed, in some settings 
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reduced translation promotes resistance to external stressors (Hansen et al., 2007). 
Additionally, treatments that reduce translation may act to promote the synthesis of 
proteins involved in other components of the PN that contribute to proteostatic 
maintenance  (Hansen et al., 2007; McColl et al., 2010; Rogers et al., 2011) . Based on 
this, it has been hypothesized that decreased rates of translation and cell proliferation 
shift cells to a state that favors the allocation of resources to maintenance and repair 
(Drake et al., 2015; Hansen et al., 2007), consistent with the disposable soma theory of 
aging. This shift would also decrease rates of growth, and is therefore a potential link 
between inhibition of mTOR and lifespan extension.  
The capacity for protein folding also decreases with age, a phenomenon that 
contributes to an accumulation of damaged proteins (Stadtman, 1992). In model 
organisms, the ability of protein chaperons to maintain proteostasis decreases with age 
(Ben-Zvi, Miller, & Morimoto, 2009). The capacity of protein folding mechanisms is 
implicated in lifespan extension. Function of the HSP family of chaperones is required 
for CR lifespan extension in nematodes (Morley & Morimoto, 2003), and long-lived IIS 
mutants show increased stress resistance through induction of the HSP, hsp-16A 
(Walker & Lithgow, 2003). Additionally, overexpression of hsp22 is sufficient for lifespan 
extension in Drosophila (Morrow, Samson, Michaud, & Tanguay, 2004).  
As discussed, proteins that cannot properly be refolded are targeted for 
degradation by the ubiquitin-proteasome system, or the autophagy-lysosomal system. 
Damaged proteins must be degraded and then resynthesized in order for proteostasis 
to be maintained. Autophagic clearance of damaged proteins decreases with age 
(Cuervo, 2008; Simonsen et al., 2008a; Vittorini et al., 1999). Several studies have 
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demonstrated the necessity of autophagy for lifespan extension in CR (Hansen et al., 
2008; Kailiang Jia & Levine, n.d.; Tóth et al., 2008) and IIS mutants (Melendez et al., 
2003; Tóth et al., 2008). Additionally, induction of autophagy alone is sufficient for 
lifespan extension in some cases (Simonsen et al., 2008b), and suppression of 
autophagy decreases lifespan (Tóth et al., 2008).   
Neuronal Proteostasis & Slowed Aging 
Proteostatic maintenance in the brain is a crucial area of aging research. 
Although neurodegenerative disease states are influenced by different factors, it 
appears that a general decrease of protein turnover and repair plays an important role 
(Radak, Zhao, Goto, & Koltai, 2011). Loss of proteostasis is a characteristic of many 
age-related neurodegenerative disorders (Eftekharzadeh et al., 2016; Smith & Mallucci, 
2016).  
 Mitochondrial dysfunction has been strongly implicated in ND, and some have 
proposed that neurodegeneration is caused by a loss of mitochondrial proteostasis 
(Chen & Chan, 2009). Parkinson’s disease, which is characterized by tremors and 
impaired motor control, is thought to be related to PTEN-induced kinase 1 (Pink1) and 
Parkin (Pickrell & Youle, 2015). Both Pink1 and Parkin are required for autophagic 
clearance of dysfunctional mitochondria (Narendra et al., 2010; Vives-Bauza et al., 
2010). As a result, Pink1 mutant Drosophila have abnormally large and dysfunctional 
neuronal mitochondria (Park et al., 2006). Similarly, a transgenic mouse model of PD 
showed morphologically abnormal mitochondria (Stichel et al., 2007). Mitochondrial 
protein synthesis may also play a role in ND, as decreased expression of transcriptional 
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regulators of mitochondrial biogenesis has been observed in AD patients (Sheng et al., 
2012).  
In addition to impaired mitochondrial proteostatic maintenance, reduced 
clearance of cytosolic proteins also contributes to neurodegeneration. In the case of AD, 
dementia arises and progressively worsens as synaptic regions in areas of the brain 
responsible for memory and cognition are disrupted by the deposition of self-assembling 
protein aggregates known as beta-amyloid plaques (AB) (Reddy & Beal, 2008; Selkoe, 
1994). It has been proposed that even small reductions in the rate of AB clearance can 
considerably worsen pathologies (Saido, 1998). 
The influence of proteostasis on neuronal function identifies mTOR as a potential 
mediator of central nervous system health. Complete loss of mTOR activity induces 
neuronal cell death (Choi, Kim, Ha, Kim, & Son, 2010). Alternatively, mouse models of 
AD show inappropriate activation of mTOR (Caccamo, Majumder, Richardson, Strong, 
& Oddo, 2010), and research has suggested that mTOR signaling contributes to tau 
hyperphosphorylation (Khurana et al., 2006; Meske, Albert, & Ohm, 2008). Further, 
mTOR inhibition decreases AB formation in mice, which is associated with increased 
autophagy (Spilman et al., 2010).  
Due to the effect of rapamycin on mTOR and autophagy, rapamycin has been 
proposed as a potential Alzheimer’s treatment (Bové et al., 2011). Indeed, rapamycin, 
through modulation of proteostatic maintenance and autophagy, has been 
demonstrated as protective in a variety of neurodegenerative disorders, including in 
models of AD (Dehay et al., 2010). Hyperactivation of mTOR in mouse models of AD is 
reversed by rapamycin, which reduces AB levels by induction of autophagy, prevents 
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tau phosphorylation, and restores cognitive function (Caccamo et al., 2010). Granted 
these results represent only one study using a transgenic mouse model, it appears as 
though rapamycin completely reversed the symptoms of AD. That rapamycin reduces 
AB levels and restores cognitive function has been repeated in separate models of AD 
(Spilman et al., 2010). Interestingly, rapamycin has been shown to effectively prevent 
cognitive decline in mouse models of AD when administered before, but not after, 
disease onset, suggesting an anti-aging effect of rapamycin in neuronal tissue 
(Majumder, Richardson, Strong, & Oddo, 2011). It should be noted that the use of 
rapamycin as either a treatment or prevention of ND is complicated by the fact that 
mTOR-mediated protein synthesis is required for long-term potentiation and synaptic 
plasticity (Tang et al., 2002). Additionally, one study showed that rapamycin may 
promote AB formation (Zhang et al., 2010).  
In some models of ND it is the repression of translation by rapamycin, rather than 
induction of autophagy, that alleviates symptoms. In Drosophila models of PD, 
rapamycin prevents the progressive degeneration of dopaminergic neurons specifically 
through translation inhibition (Tain et al., 2009). The finding that reduced protein 
synthesis, mediated by rapamycin, is beneficial in neurons has been repeated in other 
models of PD (King et al., 2008), as well as in models of Huntington’s disease 
(Wyttenbach, Hands, King, Lipkow, & Tolkovsky, 2008). Inhibition of mTOR shifts 
protein synthesis to predominantly 5’ cap-independent translation, which promotes 
translation of proteins involved in responses to cellular stress (Holcik & Sonenberg, 
2005), such as protein chaperones (Meyer et al., 2015), and may additionally contribute 
to rapamycin-induced neuroprotection.  
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Although recent progress has been made in understanding the effects of 
rapamycin on proteostasis in neuronal tissue, less is known about the effect of 
metformin. As discussed, one of the primary actions of metformin is to activate AMPK, 
which then inhibits mTOR. Therefore, in neurons the effect of metformin may be similar 
to rapamycin. It has been shown that increased AMPK signaling reduces AB production 
in mouse models of AD through inhibition of mTOR and induction of autophagy 
(Vingtdeux et al., 2010). In db/db obese mice, metformin improves memory and 
decreases AB transport across the blood brain barrier by decreasing the expression of 
receptor for advanced glycation end products (Chen et al., 2016). Metformin may also 
provide neuroprotection independently of AMPK. Metformin promotes 
dephosphorylation of tau by activation of protein phosphatase 2A, which does not 
require AMPK activation (Kickstein et al., 2010). In peripheral tissue metformin inhibits 
mTOR and thus protein synthesis through both AMPK dependent (Howell et al., 2017) 
and independent (Kalender et al., 2010) mechanisms. Whether metformin inhibits 
protein translation and thus promotes neuronal health in a similar manner remains to be 
seen. Additionally, in cultured cells and mice, metformin has been shown to increase 
the expression of beta-secratase 1, the enzyme thought to be primarily responsible for 
cleavage of amyloid precursor protein and the subsequent formation of AB (Chen et al., 
2009). 
Currently, it appears that both rapamycin and metformin, in some cases, provide 
neuroprotection through alterations in proteostatic maintenance. However, much is still 
unknown about these alterations in proteostatic mechanisms and how rapamycin and 
metformin may be refined or best utilized in the context of ND. Thus, accurate 
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measurements of the different components of proteostasis in the brain following 
treatment with rapamycin and metformin are needed.   
Protein Synthesis in the Context of Cell Proliferation 
The importance of proteostasis in health and disease has made measurements 
of protein synthesis a fundamental part of physiological research. The uses of protein 
synthesis measurements are decidedly varied. For example, protein synthetic rates can 
reflect proteostatic maintenance and provide insight into how cells maintain function 
during stress, as well as the wide array of adaptations and recovery processes that 
follow exposure to stress (Arnsburg & Kirstein-Miles, 2014; Miller, Drake, Naylor, Price, 
& Hamilton, 2014). Alternatively, protein synthesis occurs for the purpose of cell division 
(Grebien, Dolznig, Beug, & Mullner, 2005). These two distinct purposes of protein 
synthesis complicate interpretations of protein synthesis measurements. However, by 
simultaneously measuring the rate of both protein synthesis and cell proliferation, the 
relative proportion of protein synthesis for maintenance, repair, and adaptation, can be 
distinguished from protein synthesis for cell proliferation.   
Rates of cellular proliferation can be estimated by measuring DNA synthesis 
rates (Neese et al., 2001). Prior to dividing, a cell must double its genome so that each 
daughter cell has a complete set of genetic material (Stoeber et al., 2001). Similarly, the 
cell must double its proteome to ensure each cell possesses a full complement of 
functional proteins (Grebien et al., 2005). In this scenario, there is a proportional 
synthesis of protein and DNA. If this is considered as a ratio of the rate of protein 
synthesis to the rate of DNA synthesis (PRO:DNA), this ratio is unchanged by the fact 
that a cell is dividing.  
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Alternatively, if an existing cell synthesizes proteins for adaptations or repair, 
there would be synthesis of proteins without a concurrent synthesis of DNA. In this 
case, if protein synthesis is considered in its relationship to DNA synthesis, the ratio of 
the rate of protein to DNA synthesis would increase. Thus, measuring the rate of DNA 
synthesis simultaneously with protein synthesis allows for more accurate and insightful 
interpretations to be made about protein synthesis rates, either for proteostatic 
maintenance or cell division.  
Ratio of PRO:DNA Synthesis In Models of Slowed Aging  
Consistently, an increased ratio of PRO:DNA synthesis has been observed in 
various body tissues from models of slowed aging (Miller, Drake, Naylor, Price, & 
Hamilton, 2014). The importance of considering cell proliferation in the context of 
protein synthesis is clearly illustrated in studies using CR mice. Measuring long-term 
rates of protein synthesis using stable isotopic tracers, it was found that in multiple 
subcellular fractions, both long and short-term protein synthesis rates in skeletal 
muscle, heart, and liver of CR mice were not different from mice allowed to feed ad 
libitum (with the exception that short-term, mitochondrial protein synthesis was 
decreased by CR in liver) (Miller et al., 2013). This finding is counterintuitive, given the 
expected effect of caloric restriction on mTOR, and subsequently, protein synthesis. 
However, when the rates of protein synthesis were expressed as a ratio compared to 
DNA synthesis, clear differences emerged. For example, in calorically restricted mice, 
the ratio of PRO:DNA synthesis was increased compared to control in skeletal muscle 
in all subcellular fractions measured (Miller, Drake, Naylor, Price, & Hamilton, 2014). 
This difference can be interpreted as an increase in the rate of protein synthesis for the 
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purpose of maintenance, repair, and adaptation of existing cells, as opposed to growth 
and proliferation. Given the importance of proteostatic maintenance in aging it might be 
reasonable to expect that this characteristic is shared among other models of slowed 
aging, and this indeed the case. 
Long-lived crowded-litter mice (which are calorically restricted during postnatal 
development) show increased levels of PRO:DNA in all of skeletal muscle, heart, and 
liver (Drake et al., 2014). Rapamycin treated mice also show increased PRO:DNA 
synthesis rates (Miller et al., 2014). Finally, Snell Dwarf mice, which have decreased 
growth hormone, thyroid stimulating hormone, and prolactin due to underdeveloped 
anterior pituitary grand, show both increased lifespan and increased proteostatic 
maintenance, evidenced by an increased PRO:DNA in skeletal muscle and heart (Drake 
et al., 2015).  
Measurements of protein and DNA synthesis have provided valuable insight into 
proteostatic maintenance as it relates to slowed-aging. Differences observed across 
tissues and between models highlights the importance of considering treatment effects 
in different portions of the body separately. Heart, skeletal muscle, and livermay 
respond differently to a given treatment. Whether these effects are consistent in 
nervous system tissue in models of slowed aging has yet to be evaluated.  
Knowledge Gaps 
Measurements of protein synthesis and proteostatic maintenance have revealed 
important mechanisms underlying improved health and extended lifespan various 
models of slowed aging. Frequently, treatment effects are tissue specific. Whether or 
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not slowed aging treatments alter protein synthesis rates or proteostatic maintenance in 
the brain of models of slowed aging is an unexplored area of research. 
 
Study purpose 
The purpose of this study was to determine the impact of rapamycin and 
rapamycin plus metformin in combination on various measurements of proteostatic 


































CHAPTER III: METHODS 
 
Animal Care 
Genetically heterogeneous (UM-HET3) mice were crossbred from two different 
F1 strains: (BALB/cByJ x C57BL/6J) F1 females (JAX stock 10009) and (C3H/HeJ x 
DBA/2J) F1 males (JAX stock 10004). Animals were housed at the University of 
Michigan on a 12-hour light/dark cycle. All procedures met or exceeded the standards 
for facilities housing animals described in the Animals Welfare Act regulations, the 
Guide for the Care and Use of Laboratory Animals, and the Guide for Care and Use of 
Agricultural Animals in Agricultural Research and Teaching. 
Animal Diet Composition and Study Design 
Male and female mice were divided into two groups that received treatment diets 
at either 4 (YOUNG) or 17 (OLD) months of age. Mice from OLD and YOUNG cohorts 
were randomized into one of three treatment groups that received either a standard 
control diet (Purina 5LG6) (CON), a standard diet supplemented with rapamycin (Purina 
5LG6 with 14 parts per million rapamycin) (RAP), or a standard diet supplemented with 
rapamycin and metformin (Purina 5LG6 with 100 parts per million metformin and 14 
parts per million rapamycin) (RAP+MET). Each sex was equally represented among 
groups. Mice received treatment diet for 8 weeks prior to sacrifice, making YOUNG and 
OLD 6 and 19 months of age at sacrifice, respectively. Additionally, each treatment 
group was separated into five groups for different D2O labeling periods, which allowed 
for estimation of long-term protein synthesis rates in a time-course style experiment 
(n=3 per group/sex/timepoint). An overview of the study design is illustrated in Figure 1.  
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Figure 1. Schematic Representation of treatment groups and diet.  
 
Stable Isotope Labeling Technique   
For isotopic tracer enrichment measurements, mice received intraperitoneal 
injections of deuterium oxide (D2O) (Sigma Aldrich, St. Louis, MO, USA) relative to 60% 
of body weight as previously described (Miller et al., 2013). Subsequently, drinking 
water was supplemented with 8% D2O. In the young cohort, each of the five groups 
within dietary treatment by sex received D2O for either 1, 4, 8 15, or 32 days and was 
sacrificed upon completion of D2O treatment (Figure 2). In the old cohort mice received 
D2O for 4 (male) and 8 (female) days before sacrifice (Figure 1). Mice were fasted for 12 
hours prior to sacrifice and anesthetized by carbon dioxide. Upon sacrifice, cortex, 
hippocampus, and cerebellum were collected and immediately frozen on liquid nitrogen. 
Blood was obtained by cardiac venipuncture and bone marrow was extracted from tibia 
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using phosphate-buffered saline, and each tissue was frozen on liquid nitrogen and 
stored at -80 C° for later analysis.  
 
Figure 2. Overview of deuterium oxide (D2O) labeling scheme for the young mice 
cohort. 
  
Alanine Enrichment Analysis  
Differential Centrifugation 
Whole brain tissue compartments were combined and pulverized under liquid 
nitrogen. 40-50 milligrams of tissue was aliquoted for analysis of alanine isotopic 
enrichment. Tissue was processed by differential centrifugation as previously described 
(Miller et al., 2013). In brief, tissue was homogenized by Bullet Blender® (Next 
Advance, Troy, NY, USA) in 1:10 mitochondrial isolation buffer (100 mM KCl, 40 mM 
Tris HCl, 10 mM Tris Base, 5 mM MgCl2, 1 mM EDTA, 1 mM ATP, pH 7.5) 
supplemented with phosphatase and protease inhibitors (HALT, Thermo Scientific, 
Rockford, IL, USA). Following homogenization, tissue was centrifuged for 10 minutes at 
800g to obtain the mixed subcellular protein fraction (MIX) pellet. Supernatant from the 
MIX pellet was centrifuged at 9000g for 10 minutes to separate a mitochondria-enriched 
pellet (MITO). Supernatant from the MITO pellet was incubated on ice with equal 
volume 14% sulfosalicylic acid for one hour to precipitate cytosolic proteins before a 10 
minute 16,000g spin to obtain a cytosolic protein pellet (CYTO).  
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After the MIX and CYTO fractions were pelleted, each was washed with 500 
microliters (l) of 100% ethanol (EtOH), and was centrifuged for 1 minute at 1000g 
before the removal of EtOH. This wash was followed by a similar wash with 500 l 
water, and both washes steps repeated. Both pellets were then solubilized in 250 l 1M 
NaOH and heated for 15 minutes at 50° C while shaking at 900 rotations per minute. 
Afterwards, the NaOH solutions containing the solubilized CYTO and MIX pellets were 
added to 3 and 6 milliliters (ml) 6M HCl, respectively. The MITO pellet was washed with 
200 l mitochondrial isolation buffer #2 (100 mM KCl, 10 mM Tris-HCl, 10 mM Tris 
Base, 1 mM MgSO4, 0.1 mM EDTA, 0.02 mM ATP, and 1.5% BSA, pH 7.4) and 
centrifuged for 10 minutes at 8000g. The first addition of buffer #2 was removed, and a 
second addition of 100 l was added followed by a 10 minute 6000g spin. The MITO 
pellet was solubilized in 250 l of 1M NaOH and heated to 50° C while shaking at 900 
RPM for 15 minutes. The solubilized MITO pellet was then added to 1.5 mL 6M HCl. 
Each centrifugation was performed at 4° C and all samples were kept on ice throughout 
the procedure. All HCl solutions were incubated for 24 hours at 120° C for protein 
hydrolysis.  
Alanine Derivation and Analysis 
Protein hydrolysates were cation exchanged and dried as previously described 
(Miller et al., 2012). Dried samples were reconstituted in 1 mL of Milli-Q (Millipore 
Sigma, Darmstadt, Germany) ultrapure filtered water. One-half of reconstituted sample 
(500 l) was combined with 500 l acetonitrile, 50 l 1M K2HPO4, and 20 l 
pentafluorobenzyl bromide. Samples plus reagents were vortexed and incubated for 1 
hour at 100° C. Following incubation, 600 l ethyl acetate was added and samples were 
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vortexed vigorously. The organic layer was extracted, dried under nitrogen gas, and 
reconstituted in 700 l of ethyl acetate for analysis by gas chromatography/mass 
spectrometry (GC-MS) (Agilent Technologies, GC 5975C/MS7890A). Using a DB225 
gas chromatograph column, temperature was increased from 100 C° to 225 C° at a rate 
of 10 C° per minute. The mass-to-charge ratios (m/z) of 448, 449, and 450 were 
measured for the pentafluorobenzyl-N,N-di(pentafluorobenzyl)alanine derivative and 
quantified using ChemStation software (Agilent Technologies, Santa Clara, CA, USA). 
Deuterium enrichment was calculated as the M+1 mass isotopomer (449) divided by the 
sum of the M+0 (448) and M+1 (449) mass isotopomers (Hellerstein & Neese, 1999). 
Deuterium enrichment of alanine was used to estimate the proportion of newly 
synthesized protein by dividing the deuterium enrichment of alanine by the precursor 
enrichment from body water. Body water enrichment was estimated using the deuterium 
content of extracted plasma. The fraction of newly synthesized tissue alanine was then 
adjusted for precursor enrichment using mass isotopomer distribution analysis (MIDA) 
(Hellerstein & Neese, 1999).  
Body Water Enrichment Analysis 
Body Water Derivation and Analysis 
Body water enrichment of D2O was measured from plasma as previously 
described (Drake et al., 2015). 125 l of plasma was heated overnight at 80 C° for the 
extraction of water and D2O.  After cooling to room temperature, 2 l of 10 mM NaOH 
and 20 l of HPLC grade acetone was added to each sample. Samples were vortexed 
and incubated overnight at room temperature. Next, 200 l of hexanes was added, and 
each sample vortexed. The organic layer was transferred to gas chromatography vials 
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using 200 l pipette tips filled with sodium sulfate. The m/z ratios of 58 and 60 were 
measured and quantified using ChemStation software (Agilent Technologies, Santa 
Clara, CA, USA). Analysis was performed on GC-MS (Agilent Technologies GC 
5975C/MS7890A) in tandem on EI mode with a DB-17MS column.  
DNA Enrichment Analysis  
DNA Isolation and Derivation 
DNA was isolated with QIAamp DNA mini kit using 30 milligrams whole brain 
tissue and bone marrow according to manufacturer instructions (Qiagen, Valencia, CA, 
USA). Following extraction, samples were incubated overnight at 37° C with nuclease 
S1 and potato acid phosphatase. The next day, 80 l glacial acetic acid and 100 l 
pentafluorobenzyl hydroxylamine solution was added and samples were incubated for 
30 minutes at 100° C. Samples were cooled to room temperature and 1 ml acetic and 
hydride and 100 l n-methylimidazole were added. Samples were allowed to cool to 
room temperature and 2 ml molecular biology grade water and 800 l methylene 
chloride were added. Each sample was vortexed and the organic layer extracted. A 
second addition of 800 l methylene chloride was extracted, combined with the first, and 
transferred to glass tubes containing granular, anhydrous sodium sulfate. Samples were 
dried under vacuum and reconstituted in 70 l ethyl acetate and analyzed by GC-MS 
(Agilent Technologies, GC 7890B/MS 7697) with a DB-17MS column using negative 
chemical ionization. Helium was used as a carrier gas and methane as the reagent. The 
pentafluorobenzyl triacetyl derivative of purine deoxyribose was measured for the 
fractional molar isotope abundances at m/z 435 and 436 and quantified using 
ChemStation software (Agilent Technologies, Santa Clara, CA, USA).  
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Protein Quantification and Aggregation Assays 
Tissue Homogenization and Lysis 
40 milligrams of pulverized whole brain was homogenized in 300 l lysis buffer 
(100 mM NaF, 50 mM HEPES, 12 mM Sodium Pyrophosphate, 10 mM EDTA, 1% 
100X-Triton by volume) with phosphatase and protease inhibitors (HALT, Thermo 
Scientific, Rockford, IL). Samples were centrifuged at 16,000g for 20 minutes. 
Supernatant was removed and protein content was quantified by bicinchoninic acid 
assay (BCA) (Thermo Fisher, Rockford, IL).  
Protein Quantification by Western Blot 
Each sample of homogenized tissue was then diluted so that total protein 
concentration was equal to 2 g/l. Samples were then incubated with Lamelli buffer. 30 
g protein was loaded into a 26-well, 10-20% Tris-HCl gel (Criterion, Bio-Rad, Hercules, 
CA) and separated using 12% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) at 100V. Samples were transferred to a polyvinylidene 
difluoride (PVDF) membrane at 4° C for 45 minutes at 100V in transfer buffer (20%w/v 
methanol, 0.02% SDS, 192 mM glycine, 25mM Tris, pH8.3). Membranes were blocked 
in 5% milk in Tris Buffered Saline with Tween (TBST) (get from SOP) for 2 hours at 
room temperature. before primary antibodies were added. Antibodies were purchased 
from Cell Signaling Technologies (Boston, MA; RpS6 #2217S, RpS6 phospho-
Ser[240/244] #4858S, AMPK #2532S, phosphor-AMPK[Thr172] #2531S). Blots were 
incubated overnight in primary antibodies at a concentration of 1:1000 in 5% BSA and 
TBST at 4° C. Membranes were rinsed in TBST and incubated with anti-rabbit 
horseradish peroxidase-conjugated secondary antibody diluted to a concentration of 
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1:5000 in 5% milk in TBST. After a 1 hour room temperature incubation membranes 
were rinsed in TBST followed by chemiluminescence detection (SuperSignal West 
Femto Maximum Sensitivity Substrate, Thermo Scientific, Rockford, IL). Images were 
captured and densitometry was analyzed using a UVP Bioimaging system (Upland, 
CA). Blots were first probed for phosphorylated proteins. Membranes were then stripped 
(Restore Western Blot Stripping Buffer, Thermo Scientific, Rockford, IL) and re-probed 
for total protein.  
Protein Aggregation Assay 
Protein aggregation was measured in homogenized, lysed tissue samples using 
a PROTEOSTAT® protein aggregation assay (ENZ-51023, Enzo Life Sciences, Inc., 
Farmingdale, NY, USA) according to the manufacturer instructions. A standard curve 
was generated using PROTEOSTAT® protein aggregation standards (ENZ-51039, 
Enzo Life Sciences, Inc., Farmingdale, NY, USA), also prepared according to 
manufacturer instructions. Samples and standards were prepared in duplicate on a 96-
well plate. Mean optical density values were converted to percentage of aggregated 
protein based on values obtained from the standard curve.  
Statistics 
Statistical Analysis was performed using PRISM GraphPad 7 Software 
(Graphpad Software, La Jolla, CA). In the young cohort, nonlinear regressions of 
fraction new were calculated using mean values for each timepoints in all subcellular 
protein fractions for the three treatment groups in both sexes. Slope of the curve for 
each nonlinear regression (k) was calculated. Within sex and age comparisons of k 
values for each fraction, protein abundance measured by Western blot, and protein 
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aggregation content between groups were made using Tukey’s multiple comparison 
test. Between sex and between age comparisons of k for each fraction and group, as 
well as individual protein content, and concentration of aggregated protein were made 
using Sidak’s multiple comparisons test. Fraction new DNA as well as PRO:DNA 
synthesis ratios were compared in the 32 day timepoint of the young cohort using 
Tukey’s multiple comparisons test. In the older cohort, fraction new was analyzed for 
individual timepoints in male (8 days D2O labeling) and female (4 days labeling) using 































CHAPTER IV: RESULTS 
 
Rapamycin and Metformin Affect Long-Term, Subcellular Brain Protein Synthesis 
Rates in Young Female Mice 
In young male mice, mitochondrial, cytosolic, and mixed protein synthesis rates 
were not different in any group (Figure 3). In young female mice mitochondrial protein 
synthesis value was lower in RAP+MET compared to CON and RAP (p<0.05) (Figures 
4A and 4B). Additionally, cytosolic protein synthesis was lower in young female 
RAP+MET than in CON (p<0.05) (Figures 4C and 4D). In the mixed protein fraction, no 
differences in synthesis rates were observed in among treatment groups in female mice 
(Figures 4E and 4F).   
Protein Synthesis Rates Differ Between Male and Female Mice in Each Treatment 
Group  
When subcellular protein synthesis rates were compared between male and 
female mice for each group, it was found that there was a main effect of sex (p<0.05) in 
the CON group, with females showing greater protein synthesis rates (p<0.05) (Figure 
5A). Additionally, Female CON mice had higher rates of mixed fraction protein synthesis 
compared to males (p<0.05) (Figure 5A). In RAP, no differences were observed 
between sexes (Figure 5B). In RAP+MET, there was a main effect of sex (p<0.05) and 
a sex by fraction interaction (p<0.05), with males demonstrating higher rates of protein 




Rapamycin and Metformin Decrease Subcellular Protein Synthesis Rates in Older 
Mice 
Due to limited tissue availability, only individual time points were analyzed for 
older mice (Figure 6A-6F). Analysis was made on male mice that underwent 8 days of 
D2O labeling, and females following 4 days of D2O treatment. In males, RAP showed 
lower mitochondrial protein fraction new compared to CON (p<0.05) (Figure 6A). Also in 
male RAP, cytosolic protein synthesis was decreased compared to CON (P<0.05) 
(Figure 6B), while decreased mixed fraction protein synthesis in male RAP mice 
approached statistical significance decreased synthesis rates compared to RAP+MET 
(p=0.084) (Figure 6C). In females, mixed protein synthesis was lower in RAP and 
RAP+MET compared to CON (p<0.05) (Figures 6D). In old female RAP mice cytosolic 
protein synthesis also approached statistical significance (p=0.067) (Figure 6F), and no 
differences were found between treatment groups for mitochondrial protein synthesis 
(Figure 6B).  
DNA Synthesis is Affected Differently By Rapamycin and Metformin in Male and 
Female Mice 
Brain has low rates of cell proliferation, and due to low DNA enrichment values 
only data for the final timepoint (day 32) for young mice were included in the analysis. In 
young male mice RAP, but not RAP+MET, decreased the rates of DNA synthesis 
compared to CON (p<0.05) (Figure 7A). In young female mice, both RAP and 




Rapamycin Increases PRO:DNA in Young Male Mice 
To evaluate the influence of RAP and RAP+MET on proteostatic maintenance, 
protein and DNA synthesis for the 32 day timepoint for young male and female mice 
was expressed as a ratio (PRO:DNA) in (Figure 8). In male mice, PRO:DNA synthesis 
was increased in all protein fractions in RAP compared to CON (p<0.05) (Figures 8A, 
8C, and 8E). Conversely, RAP and RAP+MET showed decreased PRO:DNA synthesis 
rates in young female mice compared to CON (Figures 8B, 8D, and 8F). 
Rapamycin Decreased Aggregated Protein Content in Young Male Mice 
In young male mice RAP decreased the percentage of protein aggregates 
relative to total protein (P<0.05) (Figure 9A). However, no other differences were 
observed in any treatment group in either age group or sex (Figures 9B-9D). In addition, 
no differences in protein aggregation were observed when male and female mice were 
compared within young and old cohorts, or in comparisons between age in male and 
female mice (Figures 10A-10D).  
Rapamycin and Rapamycin Plus Metformin Decrease Phosphorylated RPS6 in 
Older Mice 
In the young cohort, the proportion of p-RpS6 compared to total RpS6 was not 
different in either male or female mice (Figures 11A and 11B). In older male mice, RAP 
decreased p-RpS6 (P<0.05) (Figure 11C). In female mice, both RAP and RAP+MET 
decreased p-RpS6 relative to total RpS6 compared to CON (P<0.05) (Figure 11D). No 
statistically significant differences in overall p-RpS6 content were observed between 
treatment groups in any age or sex (Figures 12A-12D). Total RpS6 was significantly 
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higher in RAP and RAP+MET in old female mice (P<0.05) (Figure 13D), and no other 
treatment differences were observed (Figures 13A-13C).  
Neither Treatment Group Demonstrated Increased Levels of Activated AMPK in 
Any Age or Sex 
When comparisons were made between groups and among age and sex, no 
differences in p-AMPK relative to total AMPK were detected (Figures 14A-14D). Both 
RAP and RAP+MET showed increased absolute levels of p-AMPK in young female 
mice (P<0.05) (Figure 15B), but not in other old mice or either age in males (Figures 
15A-15D). No differences were observed in total AMPK content in any age or sex 































Figure 3. Nonlinear regressions and slope of the regression (k) of fraction new 
protein for mitochondrial (A and B), cytosolic (C and D), and mixed (E and F) 




Figure 4. Nonlinear regressions and slope of the regression (k) for fraction new 
protein of mitochondrial (A and B), cytosolic (C and D), and mixed (E and F) 
fractions in young female mice. #Statistically different from CON and RAP 





Figure 5. Comparisons between male and female k for each group in young mice. 
*Significantly different from female (p<0.05). ^Main effect of sex (P<0.05). 






Figure 6. Fraction new at individual time points for mitochondrial, cytosolic, and 
mixed protein fractions in older mice. *Significantly different from CON (p<0.05). 
#Significantly different from CON and RAP+MET (p<0.05) Values expressed as 







Figure 7. DNA fraction new for young mice at the 32 day timepoint. #Significantly 
different from CON and RAP+MET (p<0.05). *Significantly different from CON 






Figure 8. Ratio of PRO:DNA synthesis at the 32 day timepoint for young mice. 
#Significantly different from CON and RAP+MET (p<0.05). *Significantly different 






























Figure 9. Protein aggregation as a percentage of total protein. *Significantly 





















Figure 10. Comparisons of protein aggregation content between male and female 
and young and old mice. Values expressed as mean +/- SEM. 
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Figure 11. Phosphorylated RpS6 relative to total RpS6 in young and old mice.  
*Significantly different from CON (p<0.05). Values expressed as mean +/- SEM. 
 
 
Figure 12. Phosphorylated RpS6 normalized to tubulin in young and old mice. 




Figure 13. Total RpS6 normalized to tubulin in young and old mice. *Significantly 
different from CON (p<0.05). Values expressed as mean +/- SEM. 
 
 
Figure 14. Phosphorylated AMPK relative to total AMPK in young and old mice. 




Figure 15. Phosphorylated AMPK normalized to tubulin in young and old mice. 
*Significantly different from CON (P<0.05). Values expressed as mean +/- SEM. 
 
 
Figure 16. Total AMPK normalized to tubulin in young and old mice. Values 
expressed as mean +/- SEM. 
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CHAPTER V: DISCUSSION 
 
Summary of Findings 
This study is the first to report the use of deuterium oxide as a stable isotopic 
tracer for measurements of protein and DNA synthesis in the brain. The primary findings 
of this study are that in the brains of UM-HET3 mice, treatment with RAP and 
RAP+MET differently affects components of proteostatic maintenance, and that there 
are differences between sexes in brain turnover with and without lifespan extension 
treatments. These data are important because they provide evidence that protein 
turnover in the brain is malleable, and that sex should be considered when targeting 
treatments for brain aging and disease.   
Novel Insights and Outcomes 
 The use of deuterium oxide as a stable isotopic tracer for measurements of 
biogenesis in cell culture (Miller, Wolff, Peelor, Shipman, & Hamilton, 2015) and in vivo 
is well established (Drake et al., 2013, 2015; Miller, Robinson, Bruss, Hellerstein, & 
Hamilton, 2012). However, this is the first study to demonstrate that deuterium oxide 
can be used to assess protein and DNA synthesis rates in whole brain. In addition, 
these results show that measurements of protein and DNA synthesis rates using D2O in 
mouse brain are sensitive enough to detect sex differences, as well as differences in 
response to treatment. These differences were consistent even in the relatively shorter-
term measurements used in analysis of protein synthesis in the older cohort. In addition 
to our proteostatic assessments in peripheral tissues, we now add D2O approaches use 
for evaluation of proteostasis in the brain. This approach represents a new methodology 
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for studying protein and DNA synthesis rates in the central nervous system, a crucial 
area for research on aging and neurodegenerative disease.   
 The present study is the first study to examine the effects of two treatments 
known to extend lifespan on multiple characteristics of proteostatic maintenance in the 
brain. Here, we have demonstrated that treatment with RAP and RAP+MET differently 
affects subcellular protein synthesis rates, DNA synthesis rates, PRO:DNA synthesis 
ratios, protein aggregation, and activity in the mTOR signaling pathway in the brain. 
These findings support existing research that implicates the use of slowed aging 
treatments to study, prevent, or treat age-related cognitive decline and 
neurodegeneration (Dehay et al., 2010; Markowicz-Piasecka et al., 2017; Moll, Cohen, 
& El-Ami, 2014). 
Sex Differences in Outcomes of Proteostatic Maintenance 
 Notably, the responses to RAP and RAP+MET were consistently different 
between sexes in young mice. Sex-dependent differences in either the presence or 
magnitude of response to a given dose of rapamycin have previously been reported 
(Fischer et al., 2015; Fok et al., 2014; Miller et al., 2014) and attributed to elevated 
levels of blood rapamycin in female mice compared to males . Although blood levels of 
rapamycin were not measured in the current study, a difference in bioavailable 
rapamycin is a plausible explanation for the different protein synthesis rates in female 
RAP+MET compared to males. It should be acknowledged that male and female 
comparisons were not made in the old cohort, as different timepoints were used for 
each sex.  
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 In addition to discrepancies in the presence of an effect of treatment between 
sexes, we found that the direction of phenotypic change in response to RAP and 
RAP+MET was also distinct between male and female mice. In young male mice RAP 
decreased DNA synthesis, whereas both RAP and RAP+MET increased DNA synthesis 
in female mice. Differences in the direction of a phenotypic change in response to 
rapamycin treatment in mice has previously been reported (Fischer et al., 2015). The 
single study reporting such differences found that female mice had increased body 
mass and body fat (without increased food consumption), while males had lower body 
mass and body fat in response to rapamycin treatment (Fischer et al., 2015).  
Brain Protein Synthesis Rates in Comparison to Other Body Tissues 
 Data that directly compares synthesis rates in brain to other body tissues is 
limited. It has been shown that brain has among the lowest protein synthesis rates of 
any tissue in mice (Shahbazian, Jacobs, & Lajtha, 1987; Wu, MacCoss, Howell, 
Matthews, & Yates, 2004). When brain protein synthesis data from the current study are 
compared to protein synthesis rates in other tissues from the same animals, the results 
are in agreement with previous findings (Sayegh & Lajtha, 1989; Shahbazian et al., 
1987). Consistent with published literature, protein synthesis rates in each subcellular 
fraction in brain are, in general, much lower than those in liver. For example, in young 
male CON, the k value for cytosolic and mixed protein synthesis in brain was 0.1212 
and 0.0789, respectively. In contrast, liver k values for were 0.2469 for cytosolic protein 
synthesis 0.3088 for mixed protein synthesis. However, protein synthesis rates in brain 
were considerably higher than in skeletal muscle (cytosolic=0.02246, mixed=0.01792), 
and comparable to those in heart (cytosolic=0.07296 and mixed=0.06147).  
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 It also appears that, in general, mitochondrial protein synthesis rates may be 
higher in brain (k=0.0858 in young male CON) than in heart (k=0.0510) and skeletal 
muscle. (k=0.0216). Mitophagy is reduced in some types of ND (Chen & Chan, 2009), 
and it is possible that mitophagy is important in tissue that has high rates of 
mitochondrial protein synthesis, such as brain. If mitochondrial protein synthesis is not 
matched by mitophagic processes, dysfunctional mitochondria may accumulate, leading 
to the generation of ROS, protein damage, and potentially protein aggregation.  
Do Rapamycin and Metformin Slow Aging? 
 The results in this thesis could be used to determine if the lifespan-extending 
effect of the slowed aging treatments, RAP and RAP+MET, also extend healthspan. 
Although the lifespan-extending effects of rapamycin (Harrison et al., 2009; R. A. Miller 
et al., 2014) and rapamycin with metformin (Strong et al., 2016) are well documented, 
whether such lifespan extension is a result of slowed aging is controversial. It has been 
proposed that rapamycin extends lifespan in mice primarily by reducing the incidence of 
cancer, and that the effects of rapamycin on aging are minimal (Neff et al., 2013). 
However, experimental evidence is conflicting (Bitto et al., 2016; Wilkinson et al., 2012) 
and the notion that rapamycin limited effects on aging has been contested 
(Blagosklonny, 2013b; Johnson, Martin, et al., 2013). Previously, we have demonstrated 
an increased ratio of PRO:DNA synthesis in multiple tissues from long-lived model 
organisms (Drake et al., 2014, 2015; Miller et al., 2014), and have proposed that 
PRO:DNA synthesis ratios may be a biomarker for slowed aging (Miller et al., 2014). In 
the current study, RAP increased the PRO:DNA ratio in male mice, but RAP and 
RAP+MET decreased the PRO:DNA ratio in young female mice. It is plausible that the 
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decreased PRO:DNA synthesis ratio reflects a negative effect of treatment. This 
hypothesis should be tested with additional measurements and functional outcomes, 
and with methods that isolate the different cell types in the brain. Importantly, the levels 
of DNA synthesis in brain are extremely low compared to other tissues (Drake et al., 
2013, 2015). Thus, the PRO:DNA synthesis ratio in the brain may only weakly implicate 
functional outcomes and aging, if at all.   
Limitations 
 The use of genetically heterogeneous UM-HET3 mice in the current study is 
simultaneously a strength and weakness. The utilization of mice that are genetically 
distinct from one another increases the translatability of findings to human physiology. 
However, genetic manipulation is typically required to study human ND in mice, and in 
the absence of genetic intervention mice are not predisposed to neurodegeneration 
(source). In this way, the use of UM-HET3 mice in the current study limits inferences 
that can be made regarding human brain physiology. In addition, it is possible that 
important treatment effects on proteostatic maintenance in the brain that would be 
observed in humans were not detected. For example, both treatments had a minimal 
effect on the amount of protein aggregation in whole brain homogenates. This is 
somewhat unexpected, given that rapamycin promotes autophagy (source). A 
reasonable explanation is that RAP and RAP+MET generally failed to reduce protein 
aggregation because there was not an appreciable amount of protein aggregation to 
reduce. If similar measurements were made  older humans, it is possible that treatment 
with rapamycin may have a marked effect on protein aggregation, as has been 
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demonstrated in vitro (Caccamo et al., 2013; Dehay et al., 2010) and in transgenic 
models of ND (Viscomi et al., 2012). 
 In contrast to protein synthesis measurements made in the young cohort, which 
utilized multiple timepoints, measurements of protein synthesis in the older cohort were 
made using single time points. This discrepancy in measurements made between the 
young and old cohorts opens the possibility that important differences in protein 
synthetic responses to treatment were missed. Further, we were unable to make 
comparisons of protein synthesis rates between young and old mice, which may have 
revealed an influence of age on neuronal protein synthesis, particularly following 
treatment with RAP and RAP+MET.  
 Finally, further insight on the effects of RAP and RAP+MET on brain health and 
aging could be gained if current data was coupled to functional outcomes. As 
discussed, it is possible that a decreased PRO:DNA synthesis ratio, or decreased brain 
protein synthesis in general, would reflect dysfunctional cellular processes that could 
impair motor and cognitive function. Alternatively, decreased PRO:DNA synthesis ratios 
in the brain may indicate a reduced need for protein turnover. The addition of functional 
outcomes to future studies would help to elucidate the significance of alterations in the 
PRO:DNA synthesis ratio in the brain. Incorporation of functional outcomes is 
particularly important as the influence of protein synthesis on ND is not straightforward. 
In some models of ND, decreased translation improves symptoms. At the same time, 




Conclusions and Future Directions 
 Results from the current study are the first to demonstrate the effect of rapamycin 
and rapamycin plus metformin on various aspects of proteostatic maintenance in the 
brain. Additionally, these results show that deuterium oxide can be used as a stable 
isotopic tracer to measure protein and DNA synthesis rates in the brain. The principle 
finding is that measurements of proteostasis-related outcomes in the brain in response 
to treatment with RAP and RAP+MET are strikingly different between sexes. Future 
studies should address the relevance of these measurements as they relate to 
functional outcomes. Finally, comparable measurements made in transgenic models of 
ND could increase our understanding of the underlying causes of neurodegeneration, 
as well how they may be treated and prevented. The use of slowed aging treatments, 
such as RAP and RAP+MET, remains a promising and unexplored area of 
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